Ruthenium-porphyrin conjugates with cytotoxic and phototoxic antitumor activity

Journal of Medicinal Chemistry

Volumn 53, Issue 12, 2010, Pages 4678-4690

  Gianferrara, Teresa ^a   Bergamo, Alberta ^b   Bratsos, Ioannis ^a   Milani, Barbara ^a   Spagnul, Cinzia ^a   Sava, Gianni ^a,b   Alessio, Enzo ^a  

^a UNIVERSITY OF TRIESTE   (Italy)

^b Callerio Foundation   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PORPHYRIN DERIVATIVE; RUTHENIUM DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CELL CULTURE; CELL GROWTH; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG CONJUGATION; DRUG STRUCTURE; DRUG SYNTHESIS; EPITHELIUM CELL; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; PHOTOTOXICITY;

ANTINEOPLASTIC AGENTS; CELL LINE; CELL LINE, TUMOR; COORDINATION COMPLEXES; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; LIGHT; PHOTOSENSITIZING AGENTS; PORPHYRINS; RUTHENIUM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77953805075     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm1002588     Document Type: Article

References (87)

1. Levina, A.; Mitra, A.; Lay, P. A. Recent developments in ruthenium anticancer drugs Metallomics 2009, 1, 458-470
2. Bruijnincx, P. C.; Sadler, P. J. Controlling platinum, ruthenium, and osmium reactivity for anticancer drug design. In Adv. Inorg. Chem., van Eldik, R.; Hubbard, C. D., Eds.; Elsevier: Amsterdam, 2009, pp 1 - 62.
3. Bruijnincx, P. C.; Sadler, P. J. New trend for metal complexes with anticancer activity Curr. Opin. Chem. Biol. 2008, 12, 197-206
4. Ang, W. H.; Dyson, P. J. Classical and nonclassical ruthenium-based anticancer drugs: towards targeted chemotherapy Eur. J. Inorg. Chem. 2006, 20, 4003-4018
5. Clarke, M. J. Ruthenium metallopharmaceuticals Coord. Chem. Rev. 2003, 236, 209-233
6. Clarke, M. J.; Zhu, F.; Frasca, D. R. Non-platinum chemotherapeutic metallopharmaceuticals Chem. Rev. 1999, 99, 2511-2534
7. Bratsos, I.; Jedner, S.; Gianferrara, T.; Alessio, E. Ruthenium anticancer compounds: challenges and expectations Chimia 2007, 61, 692-697
8. Alessio, E.; Mestroni, G.; Bergamo, A.; Sava, G. Ruthenium antimetastatic agents Curr. Top. Med. Chem. 2004, 4, 1525-1535
9. Alessio, E.; Mestroni, G.; Bergamo, A.; Sava, G. Ruthenium anticancer drugs Met. Ions Biol. Syst. 2004, 42, 323-351
10. Jakupec, M. A.; Galanski, M.; Arion, V. B.; Hartinger, C. G.; Keppler, B. K. Antitumour metal compounds: more than theme and variations Dalton Trans. 2008, 183-194
11. Hartinger, C. G.; Zorbas-Seifried, S.; Jakupec, M. A.; Kynast, B.; Zorbas, H.; Keppler, B. K. From bench to bedside-preclinical and early clinical development of the anticancer agent indazolium trans -[tetrachlorobis(1 H -indazole)ruthenate(III)] (KP1019 or FFC14A) J. Inorg. Biochem. 2006, 100, 891-904
12. Rademaker-Lakhai, J. M.; van den Bongard, D.; Pluim, D.; Beijnen, J. H.; Schellens, J. H. M. A Phase I and pharmacological study with imidazolium- trans -DMSO-imidazole-tetrachlororuthenate, a novel ruthenium anticancer agent Clin. Cancer Res. 2004, 10, 3717-3727
13. Hartinger, C. G.; Jakupec, M. A.; Zorbas-Seifried, S.; Groessl, M.; Egger, A.; Berger, W.; Zorbas, H.; Dyson, P. J.; Keppler, B. K. KP1019, a new redox-active anticancer agent: preclinical development and results of a clinical phase I study in tumor patients Chem. Biodiversity 2008, 5, 2140-2155
14. Bergamo, A.; Sava, G. Ruthenium complexes can target determinants of tumour malignancy Dalton Trans. 2007, 1267-1272
15. Peacock, A. F. A.; Sadler, P. J. Medicinal organometallic chemistry: designing metal arene complexes as anticancer agents Chem. Asian J. 2008, 3, 1890-1899
16. Dougan, S. J.; Sadler, P. J. The design of organometallic ruthenium arene anticancer agents Chimia 2007, 61, 704-715
17. Yan, Y. K.; Melchart, M.; Habtemariam, A.; Sadler, P. J. Organometallic chemistry, biology and medicine: ruthenium arene anticancer complexes Chem. Commun. 2005, 4764-4776
18. Chen, H.; Parkinson, J. A.; Morris, R. E.; Sadler, P. J. Highly selective binding of organometallic ruthenium ethylenediamine complexes to nucleic acids: novel recognition mechanisms J. Am. Chem. Soc. 2003, 125, 173-186
19. Bergamo, A.; Masi, A.; Dyson, P. J.; Sava, G. Modulation of the metastatic progression of breast cancer with an organometallic ruthenium compound Int. J. Oncol. 2008, 33, 1281-1289
20. + complexes (PTA = 1,3,5-triaza-7-phosphaadamantane) Eur. J. Inorg. Chem. 2008, 1661-1671
21. Dyson, P. J. Systematic design of a targeted organometallic antitumor drug in preclinical development Chimia 2007, 61, 698-703
22. Grguric-Sipka, S.; Stepanenko, I. N.; Lazic, J. M.; Bartel, C.; Jakupec, M. A.; Arion, V. B.; Keppler, B. K. Synthesis, X-ray diffraction structure, spectroscopic properties and antiproliferative activity of a novel ruthenium complex with constitutional similarity to cisplatin Dalton Trans. 2009, 3334-3339
23. II arene antitumor complexes in cell-free media Biochem. Pharmacol. 2009, 77, 364-374
24. Mendoza-Ferri, M. G.; Hartinger, C. G.; Nazarov, A. A.; Kandioller, W.; Severin, K.; Keppler, B. K. Modifying the structure of dinuclear ruthenium complexes with antitumor activity Appl. Organomet. Chem. 2008, 22, 326-332
25. Mendoza-Ferri, M. G.; Hartinger, C. G.; Eichinger, R. E.; Stolyarova, N.; Jakupec, M. A.; Nazarov, A. A.; Severin, K.; Keppler, B. K. Influence of the spacer length on the in vitro anticancer activity of dinuclear ruthenium-arene compounds Organometallics 2008, 27, 2405-2407
26. Das, S.; Sinha, S.; Britto, R.; Somasundaram, K.; Samuelson, A. G. Cytotoxicity of half sandwich ruthenium(II) complexes with strong hydrogen bond acceptor ligands and their mechanism of action J. Inorg. Biochem. 2010, 104, 93-104
27. Meggers, E.; Atilla-Gokcumen, G. E.; Gründler, K.; Frias, C.; Prokop, A. Inert ruthenium half-sandwich complexes with anticancer activity Dalton Trans. 2009, 10882-10888
28. Camm, K. D.; El-Sokkary, A.; Gott, A. L.; Stockley, P. G.; Belyaeva, T.; McGowan, P. C. Synthesis, molecular structure and evaluation of new organometallic ruthenium anticancer agents Dalton Trans. 2009, 10914-10925
29. Ruiz, J.; Vicente, C.; de Haro, C.; Bautista, D. A novel ruthenium(II) arene based intercalator with potent anticancer activity Dalton Trans. 2009, 5071-5073
30. For a very recent review article about Ru-arene compounds with anticancer properties see: Süss-Fink, G. Arene ruthenium complexes as anticancer agents Dalton Trans. 2010, 39, 1673-1688
31. Serli, B.; Zangrando, E.; Gianferrara, T.; Scolaro, C.; Dyson, P. J.; Bergamo, A.; Alessio, E. Is the aromatic fragment of piano-stool ruthenium compounds an essential feature for anticancer activity? The development of new Ru(II)-[9]aneS3 analogues Eur. J. Inorg. Chem. 2005, 3423-3434
32. II-[9]aneS3 complexes structurally similar to antitumor-active organometallic piano-stool compounds: preparation, structural characterization and in vitro cytotoxic activity J. Inorg. Biochem. 2008, 102, 1120-1133
33. Lottner, C.; Bart, K.-C.; Bernhardt, G.; Brunner, H. Hematoporphyrin- derived soluble porphyrin-platinum conjugates with combined cytotoxic and phototoxic antitumor activity J. Med. Chem. 2002, 45, 2064-2078 (Pubitemid 34495414)
34. Lottner, C.; Bart, K.-C.; Bernhardt, G.; Brunner, H. Soluble tetraarylporphyrin-platinum conjugates as cytotoxic and phototoxic antitumor agents J. Med. Chem. 2002, 45, 2079-2089
35. Mao, J. F.; Zhang, Y. M.; Zhu, J. H.; Zhang, C. L.; Guo, Z. J. Molecular combo of photodynamic therapeutic agent silicon(IV) phthalocyanine and anticancer drug cisplatin Chem. Commun. 2009, 908-910
36. Ben-Hur, E.; Chan, W.-S. Phthalocyanines in photobiology and their medical applications. In The Porphyrin Handbook; Kadish, K. M.; Smith, K. M.; Guilard, R., Eds.; Academic Press: Boston, 2003; Vol. 19, pp 1 - 35.
37. Pandey, R. K.; Zheng, G. Porphyrins as photosensitizers in photodynamic therapy. In The Porphyrin Handbook; Kadish, K. M.; Smith, K. M.; Guilard, R., Eds.; Academic Press: Boston, 2000; Vol. 6, pp 157 - 230.
38. Nyman, E. S.; Hynninen, P. H. Research advances in the use of tetrapyrrolic photosensitizers for photodynamic therapy J. Photochem. Photobiol., B 2004, 73, 1-28
39. Detty, M. R.; Gibson, S. L.; Wagner, S. J. Current clinical and preclinical photosensitizers for use in photodynamic therapy J. Med. Chem. 2004, 47, 3897-3915
40. MacDonald, I. J.; Dougherty, T. J. Basic principles of photodynamic therapy J. Porphyrins Phthalocyanines 2001, 5, 105-129
41. DeRosa, M. C.; Crutchley, R. J. Photosensitized singlet oxygen and its applications Coord. Chem. Rev. 2002, 233-234, 351-371
42. Weersink, R. A.; Bogaards, A.; Gertner, M.; Davidson, S. R. H.; Zhang, K.; Netchev, G.; Trachtenberg, J.; Wilson, B. C. Techniques for delivery and monitoring of TOOKAD (WST09)-mediated photodynamic therapy of the prostate: clinical experience and practicalities J. Photochem. Photobiol., B 2005, 79, 211-222 (Pubitemid 40668440)
43. Farrer, N. J.; Salassa, L.; Sadler, P. J. Photoactivated chemotherapy (PACT): the potential of excited-state d-block metals in medicine Dalton Trans. 2009, 10690-10701
44. Szaciowski, K.; Macyk, W.; Drzewiecka-Matuszek, A.; Brindell, M.; Stochel, G. Bioinorganic photochemistry: frontiers and mechanisms Chem. Rev. 2005, 105, 2647-2694
45. Ali, H.; van Lier, J. E. Metal complexes as photo- and radiosensitizers Chem. Rev. 1999, 99, 2379-2450
46. Song, R.; Kim, Y.-S.; Lee, C. O.; Sohn, Y. S. Synthesis and antitumor activity of DNA binding cationic porphyrin-platinum(II) complexes Tetrahedron Lett. 2003, 44, 1537-1540
47. James, B. R.; Meng, G. G.; Posakony, J. J.; Ravensbergen, J. A.; Ware, C. J.; Skov, K. A. Porphyrins and metalloporphyrins: potential hypoxic agents Met.-Based Drugs 1996, 3, 85-89
48. Ding, L.; Etemad-Moghadam, G.; Cros, S.; Auclair, C.; Meunier, B. Syntheses and in vitro evaluation of water-soluble cationic metalloporphyrin- ellipticine molecules having a high affinity for DNA J. Med. Chem. 1991, 34, 900-906
49. Sun, R. W.-Y.; Che, C.-M. The anti-cancer properties of gold(III) compounds with dianionic porphyrin and tetradentate ligands Coord. Chem. Rev. 2009, 253, 1682-1691
50. To, Y. F.; Sun, R. W.-Y.; Chen, Y.; Chan, V. S.-F.; Yu, W.-Y.; Tam, P. K.-H.; Che, C.-M.; Lin, C.-L. S. Gold(III) porphyrin complex is more potent than cisplatin in inhibiting growth of nasopharyngeal carcinoma in vitro and in vivo Int. J. Cancer. 2009, 124, 1971-1979
51. Wang, Y.; He, Q.-Y.; Sun, R. W.-Y.; Che, C.-M.; Chiu, J.-F. Cellular pharmacological properties of gold(III) porphyrin 1a, a potential anticancer drug lead Eur. J. Pharmacol. 2007, 554, 113-122
52. Wang, Y.; He, Q.-H.; Sun, R. W.-Y.; Che, C.-M.; Chiu, J.-F. Gold(III) porphyrin 1a induced apoptosis by mitochondrial death pathways related to reactive oxygen species Cancer Res. 2005, 65, 11553-11564
53. Vicente, M. G. H. Porphyrin-based sensitizers in the detection and treatment of cancer: recent progress Curr. Med. Chem. Anticancer Agents 2001, 1, 175-194
54. Tronconi, W.; Colombo, A.; Decesare, M.; Marchesini, R.; Woodburn, K. W.; Reiss, J. A.; Phillips, D. R.; Zunino, F. Biodistribution of haematoporphyrin analogues in a lung carcinoma model Cancer Lett. 1995, 88, 41-48
55. Woodburn, K. W.; Phillips, D. R.; Bellinger, G. C. A.; Sadek, M.; Brownlee, R. T. C.; Reiss, J. A. Synthesis and phototoxicity of a series of haematoporphyrin analogues Bioorg. Med. Chem. Lett. 1992, 2, 343-344
56. Gullotti, E.; Yeo, Y. Extracellularly activated nanocarriers: a new paradigm of tumor targeted drug delivery Mol. Pharmaceutics 2009, 6, 1041-1051
57. Maeda, H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting Adv. Enzyme Regul. 2001, 41, 189-207
58. Baban, D. F.; Seymour, L. W. Control of tumour vascular permeability Adv. Drug Delivery Rev. 1998, 34, 109-119
59. Gabrielsson, A.; Lindsay Smith, J. R.; Perutz, R. N. Remote site photosubstitution in metalloporphyrin-rhenium tricarbonylbipyridine assemblies: photoreactions of molecules with very short lived excited states Dalton Trans. 2008, 4259-4269
60. Schmitt, F.; Govindaswamy, P.; Zava, O.; Süss-Fink, G.; Juillerat-Jeanneret, L.; Therrien, B. Combined arene ruthenium porphyrins as chemotherapeutics and photosensitizers for cancer therapy J. Biol. Inorg. Chem. 2009, 14, 101-109
61. Schmitt, F.; Govindaswamy, P.; Süss-Fink, G.; Han Ang, W.; Dyson, P. J.; Juillerat-Jeanneret, L.; Therrien, B. Ruthenium porphyrin compounds for photodynamic therapy of cancer J. Med. Chem. 2008, 51, 1811-1816 (Pubitemid 351438863)
62. Rani-Beeram, S.; Meyer, K.; McCrate, A.; Hong, Y.; Nielsen, M.; Swavey, S. A fluorinated ruthenium porphyrin as a potential photodynamic therapy agent: synthesis, characterization, DNA binding, and melanoma cell studies Inorg. Chem. 2008, 47, 11278-11283
63. Davia, K.; King, D.; Hong, Y.; Swavey, S. A porphyrin-ruthenium photosensitizer as a potential photodynamic therapy agent Inorg. Chem. Commun. 2008, 11, 584-586
64. Gianferrara, T.; Bratsos, I.; Iengo, E.; Milani, B.; Ostric, A.; Spagnul, C.; Zangrando, E.; Alessio, E. Synthetic strategies towards ruthenium-porphyrin conjugates for anticancer activity Dalton Trans. 2009, 10742-10756
65. Gianferrara, T.; Giust, D.; Bratsos, I.; Alessio, E. Metalloporphyrins as chemical shift reagents: the unambiguous NMR characterization of the cis-and trans -isomers of meso -(bis)-4′-pyridyl-(bis)-4′- carboxymethylphenylporphyrins Tetrahedron 2007, 63, 5006-5013
66. 4]: synthesis and structural characterization New J. Chem. 2005, 29, 895-903
67. Lauceri, R.; Purrello, R.; Shetty, S. J.; Vicente, M. G. H. Interactions of anionic carboranylated porphyrins with DNA J. Am. Chem. Soc. 2001, 123, 5835-5836
68. Ribo, J. M.; Crusats, J.; Farrera, J.-A.; Valero, M. L. Aggregation in water solutions of tetrasodium diprotonated meso -tetrakis(4-sulfonatophenyl) porphyrin J. Chem. Soc., Chem. Commun. 1994, 681-682
69. Barrett, A. J.; Kennedy, J. C.; Jones, R. A.; Nadeau, P.; Pottier, R. H. The effect of tissue and cellular pH on the selective biodistribution of porphyrin-type photochemotherapeutic agents: a volumetric titration study J. Photochem. Photobiol., B 1990, 6, 309-323
70. Cohen, L.; Schwartz, S. Modification of radiosensitivity by porphyrins: II. Transplanted rhabdomyosarcoma in mice Cancer Res. 1966, 26, 1769-1773
71. Gianferrara, T.; Bratsos, I.; Alessio, E. A categorization of metal anticancer compounds based on their mode of action Dalton Trans. 2009, 7588-7598
72. Ochsner, M. Photophysical and photobiological processes in the photodynamic therapy of tumours J. Photochem. Photobiol., B 1997, 39, 1-18
73. He, X. Y.; Sikes, R. A.; Thomsen, S.; Chung, L. W.; Jacques, S. L. Photodynamic therapy with photofrin II induces programmed cell death in carcinoma cell lines Photochem. Photobiol. 1994, 59, 468-473
74. Dahle, J.; Steen, H. B.; Moan, J. The mode of cell death induced by photodynamic treatment depends on cell density Photochem. Photobiol. 1999, 70, 363-367
75. Luo, Y.; Chang, C. K. Initiation of apoptosis versus necrosis by photodynamic therapy Photochem. Photobiol. 1996, 66, 479-483
76. Bugelsky, P. J.; Porter, C. W.; Dougherty, T. J. Autoradiographic distribution of hematoporphyrin derivate in normal and tumour tissue of the mouse Cancer Res. 1981, 41, 4606-4612
77. Klein, A. V.; Hambley, T. W. Platinum drug distribution in cancer cells and tumors Chem. Rev. 2009, 109, 4911-4920
78. Kapp, T.; Dullin, A.; Gust, R. Mono- and polynuclear [alkylamine] platinum(II) complexes of [1,2-bis(4-fluorophenyl)ethylenediamine]platinum(II): synthesis and investigations on cytotoxicity, cellular distribution, and DNA and protein binding J. Med. Chem. 2006, 49, 1182-1190
79. Harris, A. L.; Yang, X.; Hegmans, A.; Povirk, L.; Ryan, J. J.; Kelland, L.; Farrell, N. P. Synthesis, characterization, and cytotoxicity of a novel highly charged trinuclear platinum compound. Enhancement of cellular uptake with charge Inorg. Chem. 2005, 44, 9598-9600
80. McCafferty, D. G.; Bishop, B. M.; Wall, C. G.; Hughes, S. G.; Mecklenberg, S. L.; Meyer, T. J.; Erickson, B. W. Synthesis of redox derivatives of lysine and their use in solid-phase synthesis of a light-harvesting peptide Tetrahedron 1995, 51, 1093-1106
81. Beer, P. D.; Cadman, J.; Lloris, J. M.; Martínez-Mánez, R.; Soto, J.; Pardo, T.; Marcos, M. D. Anion interaction with ferrocene- functionalised cyclic and open-chain polyaza and aza-oxa cycloalkanes J. Chem. Soc., Dalton Trans. 2000, 1805-1812
82. Kofoed, T.; Hansen, H. F.; Orum, H.; Koch, T. Synthesis and fluorescent labeling of beta-amyloid peptides J. Peptide Sci. 2001, 7, 402-412
83. Mosman, T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays J. Immunol. Methods 1983, 65, 55-63
84. Alley, M. C.; Scudiero, D. A.; Monks, A.; Hursey, M. L.; Czerwinski, M. J.; Fine, D. L.; Abbott, B. J.; Mayo, J. G.; Schoemaker, R. H.; Boyd, M. R. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay Cancer Res. 1988, 48, 589-601
85. Gross, E.; Ehrenberg, B.; Johnson, F. Singlet oxygen generation by porphyrins and the kinetics of 9,10-dimethyl-anthracene photosensitization in liposomes Photochem. Photobiol. 1993, 57, 808-813
86. 2TCP) J. Photochem. Photobiol., B 2007, 89, 131-138
87. Tamura, H.; Arai, T. Determination of ruthenium in biological tissue by graphite furnace AAS after decomposition of the sample by tetramethylammonium hydroxide Bunseki Kagaku 1992, 41, 13-17